Johnson & Johnson (JNJ)
154.18
-1.32
(-0.85%)
USD |
NYSE |
Nov 22, 11:30
Johnson & Johnson Research and Development Expense (Quarterly): 4.952B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 4.952B |
| June 30, 2024 | 3.44B |
| March 31, 2024 | 3.542B |
| December 31, 2023 | 4.48B |
| September 30, 2023 | 3.447B |
| June 30, 2023 | 3.703B |
| March 31, 2023 | 3.455B |
| December 31, 2022 | 3.71B |
| September 30, 2022 | 3.485B |
| June 30, 2022 | 3.703B |
| March 31, 2022 | 4.072B |
| December 31, 2021 | 4.283B |
| September 30, 2021 | 3.422B |
| June 30, 2021 | 3.394B |
| March 31, 2021 | 3.178B |
| December 31, 2020 | 4.213B |
| September 30, 2020 | 2.84B |
| June 30, 2020 | 2.707B |
| March 31, 2020 | 2.58B |
| December 31, 2019 | 3.232B |
| September 30, 2019 | 2.599B |
| June 30, 2019 | 2.666B |
| March 31, 2019 | 2.858B |
| December 31, 2018 | 3.224B |
| September 30, 2018 | 2.508B |
| Date | Value |
|---|---|
| June 30, 2018 | 2.639B |
| March 31, 2018 | 2.404B |
| December 31, 2017 | 3.643B |
| September 30, 2017 | 2.585B |
| June 30, 2017 | 2.296B |
| March 31, 2017 | 2.07B |
| December 31, 2016 | 2.688B |
| September 30, 2016 | 2.178B |
| June 30, 2016 | 2.264B |
| March 31, 2016 | 2.013B |
| December 31, 2015 | 2.864B |
| September 30, 2015 | 2.154B |
| June 30, 2015 | 2.129B |
| March 31, 2015 | 1.899B |
| December 31, 2014 | 2.635B |
| September 30, 2014 | 2.023B |
| June 30, 2014 | 2.005B |
| March 31, 2014 | 1.831B |
| December 31, 2013 | 2.411B |
| September 30, 2013 | 2.042B |
| June 30, 2013 | 1.946B |
| March 31, 2013 | 1.784B |
| December 31, 2012 | 2.331B |
| September 30, 2012 | 1.923B |
| June 30, 2012 | 1.766B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.58B
Minimum
Mar 2020
4.952B
Maximum
Sep 2024
3.592B
Average
3.47B
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.45B |
| Eli Lilly and Co | 2.734B |
| Merck & Co Inc | 5.862B |
| Pfizer Inc | 2.598B |
| AbbVie Inc | 2.13B |